Skip Navigation

Yescarta for Lymphoma

  • The FDA recently approved the CAR T-cell therapy, Yescarta (axicabtagene ciloleucel), for aggressive, refractory adult lymphoma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) — which was the only site in the northeast to offer Yescarta as part of the clinical trial — is pleased to make this groundbreaking therapy available to more patients now.

    The clinical trials of Yescarta (referred to as Axi-cel in the clinical trial phase) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin lymphoma responded to the CAR T-cell therapy, including 54% who had a complete response (i.e., no sign of cancer).

    Yescarta is a highly-specialized and highly personalized therapy. Patients will be evaluated carefully to determine if this therapy is appropriate for them, and will benefit from our previous experience with Yescarta, as well as our experience with other CAR T-cell therapies currently in clinical trials here.

    Learn more about CAR T-cell therapy.


  • Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), discussed the recent approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in a Facebook Live broadcast.

  • Lauren Guirschick, NP with Honorio Figueira


    Lauren Gurschick, NP, with CAR T-cell therapy patient

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information:

    For more information about lymphoma CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).